N/A
N=90
Mindfulness, Mental Fatigue, Inhibitory Control and Endurance Performance in Athletes
Mental Fatigue
Bottom Line
View on ClinicalTrials.gov: NCT05466136 ↗Enrolled (actual)
90
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: Inhibitory Control: Reaction Time — 461.01; 448.68; 444.35; 465.88 millisecond
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Mental fatigue condition (Behavioral); Control condition (Behavioral)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- National Taiwan Normal University
- Primary completion
- Oct 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Inhibitory Control: Reaction Time |
461.01; 448.68; 444.35; 465.88; 446.33; 455.91 | — |
| PRIMARY Inhibitory Control: Accuracy |
89.26; 84.32; 80.04; 89.14; 87.21; 84.16 | — |
| PRIMARY Endurance Performance: Time to Exhaustion |
807.62; 783.35; 752.94; 819.99; 794.97; 792.62 | — |
| PRIMARY Endurance Performance: Maximum Oxygen Consumption |
60.77; 61.70; 57.43; 61.39; 60.65; 58.87 | — |
| PRIMARY Changes in Neuroelectrical Activities |
-1.29; -1.47; -1.18; -0.12; -1.01; -0.89 | — |
| SECONDARY Subjective Mental Fatigue |
20.93; 26.29; 27.14; 45.26; 48.00; 51.79 | — |
| SECONDARY Objective Mental Fatigue: Reaction Time in Stroop Task |
636.66; 626.64; 617.74; 587.14; 591.25; 589.76 | — |
| SECONDARY Objective Mental Fatigue: Accuracy in Stroop Task |
84.18; 86.39; 85.48; 89.95; 90.29; 89.28 | — |
| SECONDARY Mood State |
0.148; 0.057; 0.116; 0.111; 0.121; 0.375 | — |
| SECONDARY Motivation |
87.22; 87.57; 85.89; 87.19; 90.91; 86.43 | — |
Summary
This study investigated whether trait mindfulness in athletes is associated with impairments in neurocognitive function and endurance performance resulting from mental fatigue.
Eligibility Criteria
Inclusion Criteria
- Regular sports training at least 4 hours weekly
- Normal or corrected-to-normal vision
- Right-handed
Exclusion Criteria
- Physical limitation or injury in lower limbs before and during the study
- Diagnosed or self-reported neurological disorders (e.g., epilepsy)
- Diagnosed or self-reported major psychiatric illness (e.g., major depression, schizophrenia)
Data sourced from ClinicalTrials.gov (NCT05466136). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.